In clinical trials, the new inoculation demonstrated greater protection for children and people older than 45 than the existing dengue vaccine.

Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.

Researchers overseeing the clinical trial for the first FDA-approved oral contraceptive claimed the drug gave the Puerto Rican participants power over their family planning. Critics claimed the women were exploited.

The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.

Researchers caution that it’s too soon to recommend supplements based on the results of a new study.

The group’s 7-2 ruling in favor of the therapeutic represents a shift from previous deliberations, in which data on its effectiveness was deemed insufficient.

A review by the US Office of Inspector General found that only about half of the scientists running clinical trials funded by the NIH in 2019 and 2020 appropriately recorded their findings in a federal database, as is legally required.

At Brigham and Women’s Hospital, the cancer biologist is combining research into the tumor microenvironment with the principles of neuroscience to tease apart how cancers grow—and how to stop them.

No deaths had previously been associated with the muscle-wasting treatment Zolgensma.

A lack of comprehension among some researchers about how to use ClinicalTrials.gov may be hindering public access to trial information and holding up drug study results, an investigation by The Scientist finds.

The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.

Too often, studies that aim to develop new treatments for patients fail to adequately cite and build upon research that preceded them.

A study reveals a molecular pathway linking exercise to an amped-up immune response to pancreatic cancer and greater responsiveness to treatment.

The country’s provisional go-ahead could increase pressure already being exerted on the US Food and Drug Administration to approve the therapy.